Andrew Cheng
CIK: 0001778307
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (57 total)
- Aug 12, 2026DMRA
Damora Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
30.4K shares- - May 21, 2026VERA
Vera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
17.1K shares- - Dec 9, 2025AKRO
Akero Therapeutics, Inc.
Disposition(D)Direct159.8K shares- - Dec 9, 2025AKRO
Akero Therapeutics, Inc.
Disposition(D)Direct277.1K shares- - Nov 20, 2025AKRO
Akero Therapeutics, Inc.
Gift(G)Direct74.5K shares- - Nov 12, 2025AKRO
Akero Therapeutics, Inc.
Gift(G)Direct14.7K shares- - Oct 10, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct30K shares at avg. $19.87$596K - Oct 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct30K shares at avg. $53.98$1.6M - Oct 8, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct52.2K shares at avg. $0.61$32K - Sep 11, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct1.8K shares at avg. $43.02$77K - Sep 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct158 shares at avg. $44.62$7K - Sep 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct7.3K shares at avg. $43.99$322K - Sep 10, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct1.9K shares at avg. $19.87$38K - Sep 10, 2025AKRO
Akero Therapeutics, Inc.
Exercise(M)Direct13K shares at avg. $6.36$83K - Sep 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct22.5K shares at avg. $42.99$968K - Aug 11, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct400 shares at avg. $49.44$20K - Aug 11, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct18.8K shares at avg. $48.87$919K - Aug 11, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct10.8K shares at avg. $48.07$519K - Jul 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct15.3K shares at avg. $51.73$792K - Jul 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct14.7K shares at avg. $50.57$743K - Jun 30, 2025AKRO
Akero Therapeutics, Inc.
Award(A)Direct890 shares at avg. $23.87$21K - Jun 18, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct6.6K shares at avg. $54.84$363K - Jun 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct15.2K shares at avg. $54.35$824K - Jun 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct7.8K shares at avg. $53.99$423K - Jun 10, 2025AKRO
Akero Therapeutics, Inc.
Sale(S)Direct14.8K shares at avg. $53.76$798K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 12, 2026 |  DMRA Damora Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 30,350 | - | - | Direct |
| May 21, 2026 |  VERA Vera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 17,084 | - | - | Direct |
| Dec 9, 2025 |  AKRO Akero Therapeutics, Inc. | Disposition(D) | 159,762 | - | - | Direct |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | Disposition(D) | 277,075 | - | - | Direct |
| Nov 20, 2025 | AKRO Akero Therapeutics, Inc. | Gift(G) | 74,538 | - | - | Direct |
| Nov 12, 2025 | AKRO Akero Therapeutics, Inc. | Gift(G) | 14,739 | - | - | Direct |
| Oct 10, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 30,000 | $19.87 | $596,100 | Direct |
| Oct 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 30,000 | $53.98 | $1,619,340 | Direct |
| Oct 8, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 52,212 | $0.61 | $32,110 | Direct |
| Sep 11, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 1,796 | $43.02 | $77,264 | Direct |
| Sep 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 158 | $44.62 | $7,050 | Direct |
| Sep 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 7,317 | $43.99 | $321,911 | Direct |
| Sep 10, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 1,919 | $19.87 | $38,131 | Direct |
| Sep 10, 2025 | AKRO Akero Therapeutics, Inc. | Exercise(M) | 13,022 | $6.36 | $82,872 | Direct |
| Sep 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 22,525 | $42.99 | $968,440 | Direct |
| Aug 11, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 400 | $49.44 | $19,774 | Direct |
| Aug 11, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 18,805 | $48.87 | $918,906 | Direct |
| Aug 11, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 10,795 | $48.07 | $518,916 | Direct |
| Jul 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 15,314 | $51.73 | $792,224 | Direct |
| Jul 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 14,686 | $50.57 | $742,671 | Direct |
| Jun 30, 2025 | AKRO Akero Therapeutics, Inc. | Award(A) | 890 | $23.87 | $21,243 | Direct |
| Jun 18, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 6,620 | $54.84 | $363,041 | Direct |
| Jun 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 15,158 | $54.35 | $823,883 | Direct |
| Jun 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 7,837 | $53.99 | $423,151 | Direct |
| Jun 10, 2025 | AKRO Akero Therapeutics, Inc. | Sale(S) | 14,842 | $53.76 | $797,906 | Direct |
1-25 of 57 transactions
About Cheng Andrew
Cheng Andrew (SEC CIK 0001778307) files insider reports with the SEC as Director of Damora Therapeutics, Inc. (DMRA), Director of TCGX Acquisition Corp. (TCGX) and Director of Vera Therapeutics, Inc. (VERA). Signal8 also holds filings tied to 1 other company.
Signal8 holds 29 ownership filings by Cheng Andrew (2 Form 3, 27 Form 4), filed between Sep 13, 2024 and Aug 13, 2026. Those filings report 57 transactions, from Sep 10, 2024 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cheng Andrew's filings is in WALTHAM, MA.
Recent filings by Cheng Andrew
- Aug 12, 2026: Grant or award of DMRA derivative securities (Form 4, code A).
- May 21, 2026: Grant or award of VERA derivative securities (Form 4, code A).
- Dec 9, 2025: Disposition to issuer transactions of AKRO shares (2 lines, Form 4, code D).
- Nov 20, 2025: Gift of AKRO shares (Form 4, code G).
- Nov 12, 2025: Gift of AKRO shares (Form 4, code G).
Other insiders filing for Damora Therapeutics, Inc. (DMRA)
- Jarrett Jennifer, Director, President and CEO
- Winslow Garrett, General Counsel
- Burkavage Brian, SVP, Finance
- Turtle Cameron, Director
- Landsittel Michael, Director
- Fairmount Funds Management LLC, Director